Pobierz poster

(Aby pobrać poster, kliknij ikonę PDF)

Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), 7-11 November 2018, Washington, DC, USA

  • "Novel class of small molecule direct STING agonists as a potential cancer immunotherapy"
  • “Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

Mechanisms to Therapies: Innovations in Cancer Metabolism, 9 - 11 October 2018, Bilbao, Spain

  • "Discovery of novel SHMT1/2 small molecule inhibitors for cancer treatment"

Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice, 3-5 October 2018, Dubrovnik, Croatia

  • “CDK8 inhibitor SEL120 targets AML by regulation of transcriptional programs involved in the maintenance of leukemia stem cells”

Annual Immuno-Oncology Summit, 27-31 August 2018, Boston, MA, USA

  • "Discovery of novel small molecule STING agonists as a new cancer immunotherapy"
  • “Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

AACR Annual Meeting 2018, 14 - 18 April 2018, Chicago, IL, USA

  • "Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy"
  • "CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of transcriptional programs involved in the maintenance of leukemia stem cells"
  • "Discovery of novel SHMT small molecule inhibitors for cancer treatment"

AACR Annual Meeting 2017, 1 - 5 April 2017, Washington, DC, USA

  • "Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells"
  • "Differential activity on lung adenocarcinoma cells with loss-of-function mutations of SWI/SNF protein SMARCA4"
  • "Small molecule inhibitors of SHMT1/2 validate serine metabolism as a target in the treatment of c-Myc positive solid tumors"
  • "Inhibition of CDK8 kinase with SEL120-34A allows for a personalized approach in AML"
  • "Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies"

AACR Annual Meeting 2015, 18 – 22 April 2015 in Philadelphia, PA, USA:

  • “First-in-class dual PIM/FLT3 inhibitor SEL24-B489 for the treatment of hematological malignancies”
  • “Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer”

AACR Annual Meeting 2014, 5-9 April 2014, San Diego, USA:

  • “Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies”
  • “Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases”